Plain-English translation of NCT07005128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a new drug called to a standard combination of chemotherapy and immunotherapy can help people with advanced small-cell lung cancer live longer. Small-cell lung cancer is an aggressive type of lung cancer that spreads quickly. About half of the 330 people in this study will receive the medication along with standard treatment, while the other half will receive standard treatment alone, so doctors can compare how well each approach works.
Small-cell lung cancer is very serious and patients need better treatment options. This medication works in a different way than standard chemotherapy, and researchers believe adding it might help more patients survive longer or live better with their disease.
If you join this trial, you will be randomly assigned to one of two groups. Both groups will receive chemotherapy and immunotherapy for 4 cycles (usually given every 3 weeks). One group will also receive the new medication during and after these 4 cycles, while the other group will continue with just the standard treatment. After the initial 4 cycles, you'll continue receiving maintenance treatment for a period of time. You'll have regular visits to the hospital or clinic for infusions, blood tests, and scans to monitor how you're responding.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States